Oncology Education Archives

Launch of Free MELODIC Training Programme – Greece

We are pleased to announce the launch of the free eight-week online training programme implemented in Greece within the framework of the European project MELODIC, in which Kapa3 participates as one of 13 partner organisations from 6 European countries.

The programme is addressed to doctors, nurses, other health professionals, and social care professionals working in oncology.

MELODIC is an international collaboration aimed at strengthening mental health support for young adults with cancer and their families, promoting high-quality, holistic oncology care.

Through the programme, participants will have the opportunity to develop skills in:

Assessing mental health needs using validated and evidence-based tools
Supporting families and caregivers
Delivering high-quality psychosocial care
Interprofessional collaboration
Sustaining personal and professional wellbeing

The programme is divided into an asynchronous part (on the Moodle platform), which participants can complete at their own pace, and four contact lessons, constituting the synchronous part via Zoom. Upon completion, participants will receive 5 ECTS credits and a certificate of completion.

Sessions will take place from March to April 2026.

The contribution of health professionals is crucial for the accurate assessment of mental health needs of young adults with cancer and their families, as well as for delivering high-quality, person-centred care. The MELODIC programme strengthens their skills, promoting collaboration, responsibility, and sustainable professional practice in oncology.

For further information, please contact:
Ifiyenia Anastasiou
email: ifi.k3team@gmail.com | phone: 690.62.65.170

World AIDS Day — December 1

World AIDS Day is a powerful reminder that the fight against HIV/AIDS is far from over. Despite remarkable progress in recent decades, millions of people worldwide are still living with the virus. At the same time, inequalities in access to prevention, diagnosis and treatment continue to cost lives.

Established in 1988 as the first international health-related awareness day, World AIDS Day has since served as a global call for informed action, early diagnosis, destigmatization and equitable care.

What We Know Today About HIV/AIDS

According to recent UNAIDS data, more than 39 million people are living with HIV globally — and thanks to modern treatments, they can live full and healthy lives.

The science is encouraging. Antiretroviral therapy (ART/ARVs) allows people on treatment to reach undetectable viral loads, which means they cannot transmit the virus (“Undetectable = Untransmittable”).

Yet despite this progress, new infections still occur — mainly in communities facing social exclusion, economic hardship, or limited access to healthcare services. At the same time, lack of information and persistent stigma remain major barriers that delay testing and treatment.

HIV & Cancer: An Important Connection

The link between HIV and several forms of cancer isn’t widely known, yet it is significant:

People living with HIV have a higher risk of cervical cancer due to the more persistent presence of HPV.
Increased risk is also observed for non-Hodgkin lymphoma, Kaposi sarcoma and several cancers associated with chronic viral infections.
Early diagnosis, continuous treatment and regular screening significantly reduce these risks.

At Kapa3, we have published articles on the importance of screening and patient empowerment, which you can find here: Article1, Article2, Article3, Article4, Article5.

The Situation in Greece

Greece has made important progress in recent years, thanks to the operation of Checkpoints, the support of NGOs and prevention structures, the spread of PrEP, and improved access to treatment.

In 2024, Greece recorded a small decrease (4%) in new HIV diagnoses compared to 2023, according to the Hellenic National Public Health Organization (EODY). However, underdiagnosis remains a real concern. Many people avoid timely testing due to stigma and fear of discrimination.

Prevention: What Each of Us Can Do

Testing: a simple test can save lives.
Condom use & comprehensive sexual education.
PrEP & PEP: modern and effective prevention tools.
Eliminating stigma: information and open dialogue remain our strongest forms of protection.
Supporting facilities that provide access to prevention, diagnosis and treatment.

A Human Rights Issue

At Kapa3, we believe World AIDS Day concerns all of us. Access to healthcare is a fundamental right. No one should be afraid to get tested, speak openly or seek support.

According to International Human Rights Law, discrimination based on HIV status, sexual orientation, gender identity or expression, health status (including substance use), or sex work constitutes a violation of human rights.

World AIDS Day reminds us that knowledge, prevention and solidarity save lives — and that a world without new HIV infections is possible.

Sources

UNAIDS
HIV.gov
AIDS Healthcare Foundation
EODY (Hellenic National Public Health Organization)

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

The Impact of the Kapa3 Internship Programme: 30 Young Professionals in Our First 5 Years of Operation

The Impact of the Kapa3 Internship Programme: 30 Young Professionals in Our First 5 Years of Operation

In the five years since our establishment, thirty young people have had the opportunity to learn and grow through the Kapa3 Internship Programme.

International scientific literature highlights that internships are far more than a first work experience. They serve as a fundamental mechanism of experiential learning, enabling students to connect theoretical knowledge with real-world professional contexts.

Through their involvement in a civil society organisation like Kapa3, interns developed reflective and critical thinking skills—core elements of modern professional education. By engaging with real needs and challenges, students strengthened their professional identity and gained a deeper understanding of their role as future practitioners in health and social services. In many cases, the internship at Kapa3 played a significant role in supporting their transition from university to the labour market, enhancing their confidence, social skills, and clarity of professional direction.

Furthermore, the structured field experiences offered opportunities to build professional networks, a key factor in long-term career development.

At Kapa3, the value of internships is evident across all aspects of our work. We strive to create an environment where students can deepen their academic knowledge, apply their skills to real cases, and map out the next steps of their careers with realism and self-awareness.

The result is a community of young professionals who are both socially conscious and scientifically equipped to contribute meaningfully to health and social care. We are proud to be at the forefront of education and warmly thank our partner universities for their trust and collaboration.

Biomarkers Open New Paths in Cancer Treatment in Greece

Good news for cancer patients in Greece — access to personalized treatments is now becoming a reality.

A recent decision by the Ministry of Health (ΦΕΚ Β’ 5627/20-10-2025, Απόφαση Δ3(α) 41081/2025) approves and reimburses a wider range of biomarker tests, marking an important step forward for modern oncology care.

Read the Government Gazette here

But what are biomarkers?
They are special indicators detected through molecular tests that help doctors understand the unique characteristics of each patient’s cancer. In simple terms, biomarkers act like a “compass,” guiding doctors to choose the most effective and safest treatment for every individual.

Until now, only a few biomarkers were covered by the public health system — for example, molecular signatures that determine whether a woman with early-stage breast cancer needs chemotherapy (approved in 2018), or BRCA1/2 gene tests that reveal inherited risk for breast and ovarian cancer.

The new decision significantly expands this list, adding additional biomarkers for 39 indications. This allows oncologists to tailor treatments to the specific profile of each patient’s tumor, bringing Greece closer to international standards of personalized medicine.

KAPA3, which consistently supports patient education and empowerment, welcomes this development as a vital step toward more human-centred, targeted care.

This progress brings hope, better quality of life, and greater trust in the healthcare system. It is only the beginning, but it lays strong foundations for a future where every patient has access to the right treatment, at the right time.

Learn about patient rights via KAPA3’s extensive library here

Learn more about cancer biomarkers here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Depression and Cancer Mortality: A Critical Link Across Major Cancer Types

Depression is a common but often underrecognized condition among cancer patients, affecting up to 20–30% of individuals diagnosed with the disease. Beyond its impact on quality of life, mounting evidence suggests that depression can significantly influence cancer outcomes, including survival. A recent meta-analysis of 65 cohort studies spanning colorectal, breast, lung, prostate, and mixed cancers provides compelling evidence that depression diagnosed after a cancer diagnosis is associated with a substantially increased risk of mortality.

The analysis revealed that patients with depression faced an 83% higher risk of dying from colorectal cancer, a 59% higher risk in lung cancer, a 74% higher risk in prostate cancer, and a 23% higher risk in breast cancer compared to non-depressed patients. Across mixed cancer types, depression increased the risk of cancer mortality by 38%. These findings underscore that the psychological burden of cancer is not merely an emotional challenge but a critical factor affecting survival outcomes.

Mechanisms Linking Depression and Cancer Outcomes

Depression may influence cancer progression through multiple biological and behavioral pathways. Biologically, depression is associated with chronic systemic inflammation, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, immune suppression, autonomic dysfunction, oxidative stress, and impaired DNA repair. Elevated pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), can contribute to tumor growth and metastasis. In older patients, depression may exacerbate age-related immune dysfunction, creating an environment more permissive to cancer progression.

Behaviorally, depression affects health-related actions and treatment adherence. Depressed patients are more likely to delay seeking medical care, adhere poorly to chemotherapy, radiotherapy, and hormonal therapies, and engage in unhealthy habits such as smoking, poor nutrition, and physical inactivity. Social isolation and reduced support systems further increase vulnerability, compounding the negative impact on survival.

Clinical Implications and Interventions

The strong association between depression and cancer mortality highlights the urgent need to integrate mental health care into routine oncology practice. Psychological interventions, such as cognitive-behavioral therapy (CBT), supportive-expressive therapy, and mindfulness-based approaches, have shown promise in reducing distress and improving adherence to cancer treatment. Pharmacological management, including selective serotonin reuptake inhibitors (SSRIs), may also support mental health and potentially influence cancer outcomes, though more research is needed to understand their role fully. Early identification and treatment of depressive symptoms should be considered a priority for oncologists, mental health professionals, and healthcare policymakers alike.

Limitations and Future Directions

While this meta-analysis provides robust evidence, several limitations should be noted. The observational nature of the studies prevents establishing causality, and differences in study design, depression assessment methods, and patient populations contribute to heterogeneity. Future research should explore longitudinal and randomized studies to clarify causal pathways and identify the most effective interventions to reduce depression-related mortality. Investigating the interactions between depression, inflammation, and cancer biology may also reveal targets for novel supportive therapies.

Depression is not just a psychological burden for cancer patients—it is a significant predictor of mortality across multiple cancer types. These findings call for systematic depression screening and tailored interventions as integral components of oncology care.

Organizations like Kapa3 play a vital role in supporting the mental health of cancer patients, offering resources and guidance that can improve both quality of life and treatment outcomes. Integrating psychological support into cancer care ensures that mental well-being is recognized as an essential part of the healing process.
In line with this mission, Kapa3 participates in MELODIC, a new European initiative dedicated to supporting the mental health of young adults (18–30 years old) living with or beyond cancer.

Read the original article here

KAPA3 at the ESMO Congress: Inspiration and Confirmation That We Are Moving Towards the Future

From October 17 to 20, we attended the ESMO World Congress in Berlin. The event stood out for the active participation of the Greek medical community, which led presentations on clinical data, Real-World Evidence, and up-to-date education in collaboration with the global oncology community. At the same time, Greek teams received awards in various areas (medical, nursing, institutional), inspiring us all with hope for the ongoing developments in oncology care.

Our main goal as KAPA3 was to focus on research addressing the real needs of the population within the framework of the global community. Collaborating with healthcare professionals from around the world allowed us to gather valuable knowledge and experiences. The intensive sessions and discussions broadened our understanding and prompted reflection on the next steps.

Key challenges identified for the patient advocacy community were:

Mandatory multidisciplinary assessment before starting treatment
No patient should begin treatment without undergoing a multidisciplinary assessment, including an oncology nurse, social scientist, and psychologist. This should be considered the minimum standard for all cancer patients.
Certification and quality of multidisciplinary teams
It is our duty to ensure that these teams meet quality standards. Their certification is undoubtedly complex. However, for us at KAPA3, multidisciplinary care is a fundamental criterion for service provision and must be certified. Quality care can significantly improve patient outcomes, as shown by clinical studies and research presented at this year’s congress, with potential improvements in overall survival of up to 10% (Sweden).

We are deeply proud that our work is guided by these standards precisely. In an era of remarkable progress in medicine and new therapies, we continue to strengthen the institution of research and multidisciplinary care, ensuring accessibility and patient-centered approaches aimed at quality of life.

This is the third time we have presented our efforts at an ESMO congress, in collaboration with the International University and the Nursing Department, highlighting our presence at every level. Meanwhile, trainings for other healthcare professionals take place annually within our organization in collaboration with Greek universities.

For Greek patients and their environment, we have not yet reached a point where the quality of care is considered a key objective for the entire oncology community. Our aim is to align with efforts across Europe so that, in the future, multidisciplinary assessments from the first day of diagnosis become standard practice within therapeutic protocols.

At KAPA3, we understand that quality care, inherently multidisciplinary, requires collective effort and collaboration between organizations and professionals to determine the best possible standards.